Literature DB >> 14161911

FURTHER EXPERIMENTS ON LONG-TERM CHEMOTHERAPY OF ADVANCED MURINE TUBERCULOSIS, WITH EMPHASIS ON INTERMITTENT REGIMES.

F GRUMBACH, G CANETTI, J GROSSET.   

Abstract

Entities:  

Keywords:  DRUG RESISTANCE, MICROBIAL; EXPERIMENTAL LAB STUDY; ISONIAZID; MICE; PATHOLOGY; STREPTOMYCIN; TOXICOLOGIC REPORT; TUBERCULOSIS, PULMONARY

Mesh：

Substances：

Year:  1964        PMID： 14161911     DOI： 10.1016/s0041-3879(64)80070-2

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


× No keyword cloud information.
  8 in total

1.  CHEMOTHERAPY OF TUBERCULOSIS: A BACTERIOLOGIST'S VIEWPOINT.

Authors:  D A MITCHISON
Journal:  Br Med J       Date:  1965-05-22

2.  Intermittent treatment regimens in pulmonary tuberculosis.

Authors:  M Zierski
Journal:  Lung       Date:  1979       Impact factor: 2.584

Review 3.  General considerations in intermittent drug therapy of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Postgrad Med J       Date:  1971-11       Impact factor: 2.401

4.  [New paths of chemotherapy].

Authors:  G Urbanczik
Journal:  Pneumonologie       Date:  1971

5.  A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis.

Authors: 
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

6.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

7.  Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli.

Authors:  R M McCune; F M Feldmann; W McDermott
Journal:  J Exp Med       Date:  1966-03-01       Impact factor: 14.307

Review 8.  One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics.

Authors:  Hee-Jeong Yang; Decheng Wang; Xin Wen; Danielle M Weiner; Laura E Via
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.